Ask AI
ProCE Banner Activity

Strategies for Optimizing Antiviral Treatment of Refractory CMV Infections in Solid Organ Transplant Recipients

Clinical Thought

Learn the latest on identifying refractory cytomegalovirus (CMV) in solid organ transplant recipients through viral load monitoring and how to optimize treatment with expert insights from the first author of the 2025 Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.

Released: July 31, 2025

Share

Provided by

Provided by Clinical Care Options (CCO) in partnership with ProCE

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Partners

ProCE, LLC

ProCE Banner

Target Audience

This activity is intended for physicians and clinical pharmacists, including transplant, infectious diseases, nephrology, and internal medicine specialists who care for SOT recipients with CMV infections.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Update antiviral protocols and clinical pathways for CMV prevention in high-risk kidney transplant recipients based on the latest developments and clinical data

  • Design antiviral regimens for kidney transplant recipients at high risk for CMV disease to mitigate the impact of CMV replication on patient outcomes

  • Select antivirals for CMV prophylaxis in kidney transplant recipients to minimize the impact of antiviral toxicities on transplant clinical courses

Disclosure

Primary Author

Camille Kotton, MD, FIDSA, FAST: consultant/advisor/speaker: Abbott, Merck, Qiagen, Roche, Takeda; researcher: Takeda.